ScreenerHero

GLUE Monte Rosa Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · monterosatx.com
10.32USD+1.47%Mkt Cap: 880.43M $P/E: —

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutical…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap880.43M USD
Enterprise Value258.93M USD
Revenue (TTM)28.73M USD
Gross Profit-133.63M USD
Net Income (TTM)-38.63M USD
Revenue/Share0.31 USD
Last Price10.32 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees173
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.07
PEG—
EV/EBITDA-1.49
EV/Revenue9.01
P/S29.31
P/B1.73
EPS (TTM)-1.75
EPS (Forward)-1.95
52W Range
6.53020% of range25.77
52W High25.77 USD
52W Low6.530 USD
Profitability
Gross Margin0.00%
Oper. Margin-547.84%
EBITDA Margin0.00%
Profit Margin-31.23%
ROE-16.57%
ROA-8.61%
Growth
Revenue Growth-61.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.80M USD
CapEx (TTM)4.70M USD
FCF Margin-259.16%
FCF Yield-8.46%
Net Debt-583.12M USD
Net Debt/EBITDA3.36
Balance Sheet
Debt/Equity0.17
Current Ratio10.58
Quick Ratio10.49
Book Value/Sh5.72 USD
Cash/Share7.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.00 USD
Upside (mean)+171.3%
Target Range25.00 USD – 37.00 USD
25.00+171.3% to mean37.00
# Analysts7
Ownership
Shares Out.85.31M
Float54.48M
Insiders0.56%
Institutions116.12%
Short Interest
Short Ratio17.1d
Short % Float22.94%
Short % Out.22.58%
Shares Short19.27M
Short (prev mo.)17.46M
Technical
SMA 5014.56 (-29.1%)
SMA 20018.15 (-43.1%)
Beta1.37
S&P 52W Chg16.45%
Avg Vol (30d)1.28M
Avg Vol (10d)1.34M
Technical Indicators
RSI (14)27.8
MACD-1.3607
MACD Signal-1.3513
MACD Hist.-0.0094
BB Upper14.76 USD
BB Middle11.98 USD
BB Lower9.208 USD
BB Width46.33%
ATR (14)0.7987 USD
Vol Ratio (20d)1.26x